Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Renee M McGovern

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Investigational New Drugs|October 12, 2013
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumorsDustin A Deming, Jacob Ninan, Howard H Bailey, et al.
Investigational New Drugs|October 12, 2013
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabineMatthew P Goetz, Heidi A McKean, Joel M Reid, et al.
Investigational New Drugs|May 13, 2010
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumorsMark Andrew Dickson, Dana E Rathkopf, Richard D Carvajal, et al.
The Journal of Sexual Medicine|April 24, 2019
Vaginal Diazepam for Nonrelaxing Pelvic Floor Dysfunction: The Pharmacokinetic ProfileAlyssa M Larish, Rozalin R Dickson, Rachel A Kudgus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2013
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2Beata Holkova, Jeffrey G Supko, Matthew M Ames, et al.
Investigational New Drugs|October 12, 2013
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignanciesWilliam R Schelman, Anne M Traynor, Kyle D Holen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology GroupJudith G Villablanca, Wendy B London, Arlene Naranjo, et al.
Journal of Neuro-Oncology|January 12, 2010
Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBMKurt A Jaeckle, Karla V Ballman, Caterina Giannini, et al.
Annals of Neurology|October 15, 2021
Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic ImplicationsAnna N Ligezka, Silvia Radenkovic, Mayank Saraswat, et al.
Oncotarget|March 4, 2021
Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumorsNaoko Takebe, Geraldine O'Sullivan Coyne, Shivaani Kummar, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Investigational New Drugs|October 12, 2013
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumorsDustin A Deming, Jacob Ninan, Howard H Bailey, et al.
Investigational New Drugs|October 12, 2013
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabineMatthew P Goetz, Heidi A McKean, Joel M Reid, et al.
Investigational New Drugs|May 13, 2010
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumorsMark Andrew Dickson, Dana E Rathkopf, Richard D Carvajal, et al.
The Journal of Sexual Medicine|April 24, 2019
Vaginal Diazepam for Nonrelaxing Pelvic Floor Dysfunction: The Pharmacokinetic ProfileAlyssa M Larish, Rozalin R Dickson, Rachel A Kudgus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2013
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2Beata Holkova, Jeffrey G Supko, Matthew M Ames, et al.
Investigational New Drugs|October 12, 2013
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignanciesWilliam R Schelman, Anne M Traynor, Kyle D Holen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology GroupJudith G Villablanca, Wendy B London, Arlene Naranjo, et al.
Journal of Neuro-Oncology|January 12, 2010
Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBMKurt A Jaeckle, Karla V Ballman, Caterina Giannini, et al.
Annals of Neurology|October 15, 2021
Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic ImplicationsAnna N Ligezka, Silvia Radenkovic, Mayank Saraswat, et al.
Oncotarget|March 4, 2021
Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumorsNaoko Takebe, Geraldine O'Sullivan Coyne, Shivaani Kummar, et al.
Pageof 4